Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol - Top-Institutions - MDSpire

Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol

  • By

  • Rami El Shafie

  • Jonas Willmann

  • Eleni Gkika

  • Tanja Schimek-Jasch

  • Matthias Miederer

  • Farastuk Bozorgmehr

  • Frank Griesinger

  • Farkhad Manapov

  • Petros Christopoulos

  • Thomas Hehr

  • Markus Hecht

  • Rebecca Bütof

  • Martin Stuschke

  • Matthias Guckenberger

  • Gerald Schmid-Bindert

  • Jan Meiners

  • Sascha Herzer

  • Sonja Hartmann

  • Joana Lamché

  • Stefan Rieken

  • Ursula Nestle

  • April 17, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Radiation Oncology
    • Medical Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Radiation Oncology
    • Immunotherapy

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Translational Research

  • #4

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, TX

    Key Differentiators

    • Radiation Oncology
    • Thoracic Oncology
    • Clinical Trials

  • #5

    Vanderbilt-Ingram Cancer Center
    Vanderbilt-Ingram Cancer Center

    Nashville, TN

    Key Differentiators

    • Thoracic Oncology
    • Radiation Oncology
    • Immunotherapy

Original Source(s)

Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol

  • by Rami El Shafie, Jonas Willmann, Eleni Gkika, Tanja Schimek-Jasch, Matthias Miederer, Farastuk Bozorgmehr, Frank Griesinger, Farkhad Manapov, Petros Christopoulos, Thomas Hehr, Markus Hecht, Rebecca Bütof, Martin Stuschke, Matthias Guckenberger, Gerald Schmid-Bindert, Jan Meiners, Sascha Herzer, Sonja Hartmann, Joana Lamché, Stefan Rieken, Ursula Nestle

  • April 17, 2026

Related Content

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy